Takeda Pharma: (OTC: TKPYY)
$23.43
-0.69 (-2.86%)
Volume 37,104
May 23 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 23.10 - 23.70 |
| 52wk Low - High | 20.31 - 27.86 |
| Previous Close | 24.12 |
| Avg. Volume | 23,780 |
| Industry | MED-DRUGS |
| Market Cap | 38.09 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.10 |
| PE (Forward) | 27.10 |
| Current Year Est. | 0.89 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
106 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 27.10 |
| PEG Ratio | 3.82 |
| Current Year Est. | 0.89 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-05-2013 |
| EPS Last Year | NA |
| Expected Earnings Growth | 7.10% |
Company Description
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (03/2014) |
Next Year (03/2015) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | 0.89 | 1.04 |
| Number of Estimates | 0 | 0 | 1 | 1 |
| Low Estimate | NA | NA | 0.89 | 1.04 |
| High Estimate | NA | NA | 0.89 | NA |
| Year Ago EPS | 0.63 | 0.20 | 1.52 | 0.89 |
| EPS Growth | NA | NA | -41.45% | 16.85% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| TAKEDA PHARMACT | TKPYY | 24.12 | |
|
| JAZZ PHARMACEUT | JAZZ | 61.53 | |
|
| SALIX PHARM-LTD | SLXP | 59.47 | |
|
| SANTARUS INC | SNTS | 22.28 | |
|
| USANA HLTH SCI | USNA | 68.14 | |
|
| CATALYST PHARMA | CPRX | 0.85 | |
|
| CELL THERAPEUT | CTIC | 1.29 | |
|
| CUBIST PHARM | CBST | 56.11 | |
|
| ELAN CP PLC ADR | ELN | 12.04 | |
|
| INFINITY PHARMA | INFI | 23.12 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
The Zacks Analyst Blog Highlights: AMAG Pharmaceuticals, Takeda Pharmaceutical, DISH Network, Sprint Nextel and Verizon Communications
May 23, 2013
Swiss Issue for AMAG/Takeda's Rienso
May 22, 2013
AMAG Narrows Loss; Maintains View
Apr 24, 2013
Array Presents ARRY-520 Data
Apr 10, 2013
Pfizer's Xeljanz Approved in Japan
Apr 01, 2013
Takeda Seeks Japanese Approval
Mar 28, 2013
Takeda Files Adcetris in Japan
Mar 27, 2013
NPS Pharma and Takeda Amend Deal
Mar 19, 2013
Financials
| EPS TTM | NA |
| Sales | 15,744 |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | 1.52 |
| Price/Cash Flow | 11.10 |
| Price/Sales | NA |
News
Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma - Businesswire
May 23, 2013
The Zacks Analyst Blog Highlights: AMAG Pharmaceuticals, Takeda Pharmaceutical, DISH Network, Sprint Nextel and Verizon Communications - Pr Newswire
May 23, 2013
Takeda Pharmaceutical announces president for Millennium - Datamonitor
May 22, 2013
Takeda reports higher annual net income, provides outlook for fiscal 2013 - Datamonitor
May 22, 2013
Global Vaccine Market Forecast to 2017 - M2
May 20, 2013
Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man - Prweb
May 20, 2013
Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder - Pr Newswire
May 18, 2013
AFFY, Added To Naked Short Lists Today - M2
May 17, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 1 |
| Average Target Price | NA |
| Industry Rank by ABR | 106 out of 265 |
| Rank in Industry | 15 out of 93 |
